Skip to main content

Acceleron Pharma Value Stock - Dividend - Research Selection

Acceleron Pharma

ISIN: US00434H1086, WKN: A1W5LE

Market price date: 25.09.2020
Market price: 108,14 USD




Acceleron Pharma Fundamental data and company key figures of the share

Annual reports in USD
Key figures 28-02-2020
Cash flow
Net operating cash flow -93.804.000
Capital Expenditures -3.287.000
Free cash flow -97.091.000
Balance sheet
Total Equity 449.476.000
Liabilities & Shareholders equity 504.906.000
Income statement
Net income -124.858.000
Eps (diluted) -2,380
Diluted shares outstanding 52.453.000
Net sales/revenue 73.990.000

Fundamental ratios calculated on: 25-09-2020

Ratios
Key figures 25-09-2020
Cash flow
P/C -58,73
   
P/FC -56,74
Balance sheet
ROI-24,73
ROE89,02
Income statement
P/E-45,44
Div. Yield0,00%
P/B12,26
P/S76,66


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolXLRN
Market Capitalization5.509.138.432,00 USD
CountryUnited States
IndicesNASDAQ Comp.
Sectors
Raw Data SourceUS GAAP in Millionen USD
Stock Split
Internethttp://www.acceleronpharma.com


Description of the company

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which completed Phase III clinical trials for the treatment of myelodysplastic syndromes, beta-thalassemia, and myelofibrosis; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia. The company is also developing and sotatercept for the treatment of patients with pulmonary hypertension. In addition, the company is developing ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease; and ACE-2494, which is in Phase I clinical trials for the treatment of systemic muscle disorders. It has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, http://www.acceleronpharma.com